https://academic.oup.com/bjs/article/109/2/147/6438058?login=false
With recently demonstrated success with Remestemcel-L, I imagine access costs would reduce due to increase of demand for the therapy. Plus costs of MSCs & cost to patient quality of life & ongoing care needs to also be factored in.
Another Mesoblast future success!
Cell Therapy News/Articles, page-12955
-
- There are more pages in this discussion • 5,063 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
-0.010(0.99%) |
Mkt cap ! $1.158B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | $1.00 | $1.600M | 1.586M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 101550 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 75500 | 24 |
View Market Depth
| Last trade - 14.58pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |